ZIB

Hits per page

hits 1 - 2 | 2 hits

Sorting

Electronic Resource

Propranolol steady-state pharmacokinetics are unaltered by omeprazole (1987)

Henry, D. ; Brent, P. ; Whyte, I. ; [et al.]

Springer

European journal of clinical pharmacology 33 (1987), S. 369-373

add to mindlist on the mindlist

Details

ISSN: 1432-1041

Keywords: propranolol ; omeprazole ; pharmacokinetics ; drug interaction ; healthy volunteers

Source: Springer Online Journal Archives 1860-2000

Topics: Chemistry and Pharmacology , Medicine

Notes: Summary In a randomised double-blind cross-over study, 8 normal subjects received propranolol 80 mg twice daily with omeprazole 20 mg or identical placebo each morning. Propranolol kinetics were measured on day 8 of both treatment periods. Areas under the propranolol concentration/time curves were not significantly increased by omeprazole treatment: off treatment mean 787.6, on treatment 802.5 ng−1·ml·h. Maximum and minimum steady-state propranolol concentrations were similarily unaffected. Omeprazole also failed to increase the clinical effect of propranolol, as assessed by exercise tests on Day 8 of treatment. We conclude that omeprazole in the dose likely to be used for peptic ulcer has no significant effect on the kinetics or action of propranolol.

Type of Medium: Electronic Resource

URL: http://dx.doi.org/10.1007/BF00637632

Permalink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Paper (German National Licenses)

Fulltext

Electronic Resource

Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole (1991)

CHING, M. S. ; ELLIOTT, S. L. ; STEAD, C. K. ; [et al.]

Oxford, UK : Blackwell Publishing Ltd

Alimentary pharmacology & therapeutics 5 (1991), S. 0

add to mindlist on the mindlist

Details

ISSN: 1365-2036

Source: Blackwell Publishing Journal Backfiles 1879-2005

Topics: Medicine

Notes: Omeprazole has been shown in previous studies to inhibit the hepatic metabolism of selected drugs. Quinidine is an antiarrhythmic and antimalarial agent with a low therapeutic index. We therefore examined the effect of 40 mg omeprazole daily for one week or placebo on the pharmacokinetics and pharmacodynamics of a single 400 mg dose of quinidine in 8 healthy volunteers in a double-blind crossover study.During placebo and omeprazole treatment, there was no significant difference in area under the time–plasma quinidine concentration curve, (17.0 ± 4.83 μg.h/ml, 18.6 ± 4.43 μg.h/ml, respectively; P 〉 0.2) or renal clearance of quinidine (56.2 ± 26.0 ml/min, 55.6 ± 12.7 ml/min, respectively; P 〉 0.5). Quinidine unbound fraction in plasma (0.170 ± 0.041 vs. 0.166 ± 0.041 in the presence of omeprazole; P 〉 0.5) was not altered by omeprazole. Peak plasma quinidine concentration and the time this occurred did not differ. Omeprazole also had no effect on these parameters for the metabolite 3-hydroxyquinidine. There was no significant difference in the change in the corrected Q—T interval on the electrocardiogram due to quinidine (mean area under the time versus ±Q–Tc curve = 351 ± 192 ms. h, placebo; 414 ± 303 ms. h, omeprazole) showing that quinidine pharmacodynamics were unaltered by omeprazole. We conclude that omeprazole does not affect the pharmacokinetics of quinidine.